Preclinical assessment of pain has increasingly explored operant methods that may allow behavioral assessment of ongoing pain. In animals with incisional injury, peripheral nerve block produces conditioned place preference (CPP) and activates the mesolimbic dopaminergic reward pathway. We hypothesized that activation of this circuit could serve as a neurochemical output measure of relief of ongoing pain. Medications commonly used clinically, including gabapentin and nonsteroidal anti-inflammatory drugs (NSAIDs), were evaluated in models of post-surgical (1 day after incision) or neuropathic (14 days after spinal nerve ligation [SNL]) pain to determine whether the clinical efficacy profile of these drugs in these pain conditions was reflected by extracellular dopamine (DA) release in the nucleus accumbens (NAc) shell. Microdialysis was performed in awake rats. Basal DA levels were not significantly different between experimental groups, and no significant treatment effects were seen in sham-operated animals. Consistent with clinical observation, spinal clonidine produced CPP and produced a dose-related increase in net NAc DA release in SNL rats. Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury. In contrast, ketorolac or naproxen produced increased NAc DA in animals with incisional but not neuropathic pain. Increased extracellular NAc DA release was consistent with CPP and was observed selectively with treatments commonly used clinically for post-surgical or neuropathic pain. Evaluation of NAc DA efflux in animal pain models may represent an objective neurochemical assay that may serve as a biomarker of efficacy for novel pain-relieving mechanisms.
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Introduction
Despite significant advances in understanding the neurobiology of pain, few therapies based on novel mechanisms have advanced to clinical practice [47] . Currently available therapeutic options often demonstrate inadequate efficacy at tolerated doses or are not optimal for treatment of chronic non-malignant pain because of undesirable side effects [2, 13, 30, 45] . Although many factors contribute to difficulties in the discovery of improved therapeutics, 1 hurdle has been assessment of affective dimensions of pain in the preclinical setting [28, 49] . The development of a preclinical biomarker [1] for pain relief would be highly desirable.
Commonly used output measures from preclinical models have largely focused on modulation of behavioral responses to sensory stimulation, a relevant and important component of pain (ie, allodynia) that is observed in some patients. Assessment of affective dimensions of pain, however, has been challenging, and, until recently, few approaches were in use (for a review, see Gregory et al. [31] ). Preclinical evaluation of pain using reflexive measures differs from clinical assessment, which is usually based on human self-report. This raises concerns that important components of the pain experience are not captured, possibly impeding translation of new analgesics effective in rodents to patients. Although the limitations of laboratory animals as models for the complex experience of human pain are acknowledged, pain is fundamentally aversive in animals and in humans [10, 50] . We hypothesized that it might be possible to neurochemically assess relief of pain aversiveness 
